Article Text

Download PDFPDF
Microparticles From Ovarian Carcinomas Are Shed Into Ascites and Promote Cell Migration
  1. Joshua Z. Press, MD*,
  2. Morayma Reyes, MD, PhD,
  3. Sharon J. Pitteri, PhD,
  4. Christopher Pennil, MSc*,
  5. Rochelle Garcia, MD,
  6. Barbara A. Goff, MD*,
  7. Samir M. Hanash, MD, PhD and
  8. Elizabeth M. Swisher, MD*
  1. *Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and
  2. Department of Pathology, University of Washington School of Medicine, Seattle, WA; and
  3. Division of Public Health Sciences, and Molecular Diagnostics, Fred Hutchinson Cancer Research Center, Seattle, WA.
  1. Address correspondence and reprint requests to Joshua Z. Press, MD, Division of Gynecologic Oncology, McGill University/Jewish General Hospital/Segal Cancer Center, 3755 Cote Ste Catherine, Suite E-727, Montreal, Quebec, Canada H3T 1E2. E-mail: jpress@jgh.mcgill.ca.

Abstract

Objective Microparticles are cellular-derived vesicles (0.5–1.0 μm) composed of cell membrane components, which are actively shed from the surface of various cells, including epithelial cells. We compared microparticles in ascites between women with ovarian carcinoma and women with benign ovarian pathology, and isolated tumor-derived (epithelial cell adhesion molecule [EpCAM]-positive) microparticles for functional analysis and proteomics.

Materials and Methods Cases included 8 patients with benign ovarian neoplasms and 41 with ovarian carcinoma. Ascites from a high-grade stage III serous carcinoma was used for functional and proteomic analysis. Cancer cells were isolated using EpCAM-coated beads, microparticles were isolated by ultracentrifugation/flow cytometry, and sorting was achieved using markers (eg, EpCAM). Binding and migrations assays were performed with 3 ovarian cancer cell lines. Proteomic analysis of EpCAM-positive microparticles and ascites cancer cells was performed by mass spectrometry.

Results Microparticles in benign pelvic fluid were similar to early and advanced-stage ascites (2.4 vs 2.8 vs 2.0 × 106 microparticles/mL). Advanced stage had a greater proportion of EpCAM-positive microparticles than early or benign disease (13.3% vs 2.5% vs 2.1%; P = 0.001), and serous histology had more than endometrioid (13.2% vs 1.8%; P = 0.01). Microparticles bound to the surface of 3 cultured cell lines, and were internalized into the EpCAM-positive microparticles, resulting in more cell migration than buffer alone or EpCAM-negative microparticles (P = 0.007). A dose-dependent increase was seen with increasing numbers of EpCAM-positive microparticles. Proteomics revealed that most proteins in EPCAM-positive microparticles were shared with cancer cells, and many are associated with cell motility and invasion, such as fibronectin, filamin A, vimentin, myosin-9, and fibrinogen.

Conclusions Ascites from advanced-stage and serous ovarian carcinomas contain large numbers of tumor-derived microparticles. In vitro, these microparticles bind to cancer cells and stimulate migration. Tumor-derived microparticles in ascites could mediate the predilection for peritoneal spread in serous ovarian carcinomas.

  • Ovarian cancer
  • Microparticles
  • EpCAM

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • This study was presented in abstract form at the 41st Annual Society of Gynecologic Oncologists meeting, San Francisco, CA, 2010.

  • No authors have conflicts of interest to declare.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).